NCT07152184View on ClinicalTrials.gov

Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

February 1, 2032

Study Completion Date

February 1, 2032

Conditions
Patient With Schizophrenia Spectrum DisorderNLM Classification WM 203, Psychology:Schizophrenic PsychologySchizophrenia Spectrum and Other Psychotic Disorders
Interventions
DRUG

Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup

"Biological A blood sample of up to 5 mL will be taken at visits V0, V5, and V14, for a maximum total volume of 15 mL for the study.~Behavioral Quality of life and disease assessment questionnaires will need to be completed by the patient and their caregiver."

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER